-
1.
Li PK, Chow KM, Wong TY, et al.. Effects of an angiotensin-converting enzyme inhibitor on residual renal function in patients receiving peritoneal dialysis. A randomized, controlled study. Ann Intern Med 2003: 139: 105–112.
-
2.
Suzuki H, Kanno Y, Sugahara S, Okada H, et al.. Effects of an angiotensin II receptor blocker, valsartan, on residual renal function in patients on CAPD. Am J Kidney Dis 2004; 43: 1056–1064.
-
3.
Baigent C, Landray MJ, Reith C, et al.. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet 2011, 377:2181–2192.
-
4.
Goldfarb-Rumyantzev AS, Habib AN, Bair BC, et al.. The association of lipid-modifying medications with mortality in patients on long-term peritoneal dialysis. American journal of kidney diseases: the official journal of the National Kidney Foundation 2007; 50: 791–802.
Maximizing Success with Peritoneal Dialysis: Best Demonstrated Practices
Search for other papers by Seth B. Furgeson in
Current site
Google Scholar
PubMed
Search for other papers by Isaac Teitelbaum in
Current site
Google Scholar
PubMed
© 2021 American Society of Nephrology | All Rights Reserved
Powered by: PubFactory